Skip to main content

USANA Health Sciences (NYSE:USNA) Releases FY 2021 Earnings Guidance

Tuesday, May 4, 2021 | MarketBeat

USANA Health Sciences (NYSE:USNA) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of 6.150-6.500 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.280. The company issued revenue guidance of $1.24 billion-$1.28 billion, compared to the consensus revenue estimate of $1.24 billion.

Shares of NYSE USNA opened at $91.13 on Tuesday. The stock has a market capitalization of $1.88 billion, a PE ratio of 16.88, a price-to-earnings-growth ratio of 0.96 and a beta of 0.98. The stock's fifty day simple moving average is $97.98 and its two-hundred day simple moving average is $86.56. USANA Health Sciences has a 12-month low of $68.30 and a 12-month high of $102.96.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, April 27th. The company reported $1.45 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.57 by ($0.12). USANA Health Sciences had a return on equity of 32.91% and a net margin of 10.57%. As a group, analysts forecast that USANA Health Sciences will post 5.4 EPS for the current year.

USANA Health Sciences announced that its Board of Directors has initiated a share repurchase plan on Tuesday, February 9th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 8.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

USNA has been the topic of a number of research analyst reports. Zacks Investment Research lowered USANA Health Sciences from a hold rating to a sell rating in a research report on Tuesday, April 27th. Roth Capital upped their price objective on USANA Health Sciences from $107.00 to $126.00 and gave the stock a buy rating in a research report on Wednesday, February 10th. They noted that the move was a valuation call.

In related news, President Jim Brown sold 824 shares of the firm's stock in a transaction that occurred on Friday, February 12th. The shares were sold at an average price of $84.20, for a total transaction of $69,380.80. Following the sale, the president now owns 5,415 shares in the company, valued at $455,943. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Timothy E. Wood sold 852 shares of USANA Health Sciences stock in a transaction on Thursday, February 11th. The shares were sold at an average price of $93.58, for a total transaction of $79,730.16. Following the transaction, the director now owns 852 shares in the company, valued at approximately $79,730.16. The disclosure for this sale can be found here. Insiders sold 45,340 shares of company stock valued at $4,256,473 in the last 90 days. 45.40% of the stock is currently owned by insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

See Also: What are momentum indicators and what do they show?

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Understanding Market Liquidity


8 EV Stocks To Electrify Your Growth Portfolio

If you are looking for the next hot growth market, a market at the intersection of multiple secular trends, look no further than the EV market. Electric vehicles. It may not sound like much, but the days of EV as a fringe market are over.

Think about this. There is an average of 90 million vehicles sold annually. That’s units, not dollars, total sales of vehicles topped $3.1 trillion in 2019, and the number is expected to grow over the long-term.

The EV market is less than 3.% of global vehicle sales, but it’s growing. EV is expected to account for more than 50% of the total auto-fleet by 2050, and that target could be reached much sooner if battery technology advances.

When it comes to the EV market, it’s a “rising tide lifts all ships” kind of market, but there are still some clear winners to focus on.

View the "8 EV Stocks To Electrify Your Growth Portfolio".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.